Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Regeneus Ltd. ( (AU:CMB) ) just unveiled an announcement.
Cambium Bio Limited has received shareholder approval to issue shares and options to its directors, resulting in the issuance of 4,139,650 ordinary shares and 120,000 unlisted options. This move is part of the company’s strategic efforts to align its leadership’s interests with its growth objectives in the regenerative medicine sector, potentially enhancing its market positioning and stakeholder confidence.
More about Regeneus Ltd.
Cambium Bio Limited is a Sydney-based clinical-stage regenerative medicine company specializing in innovative biologics for ophthalmology and tissue repair applications. The company leverages its proprietary human platelet lysate technology to develop novel therapeutics, with a primary focus on ophthalmology. Its lead product candidate, Elate Ocular®, targets dry eye disease, while its stem cell platform, Progenza™, is aimed at knee osteoarthritis and other tissue repair indications.
YTD Price Performance: -12.50%
Average Trading Volume: 24,448
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$4.95M
For a thorough assessment of CMB stock, go to TipRanks’ Stock Analysis page.